Article
Endocrinology & Metabolism
Yuanna Ling, Xiaoli Xiong, Jiaxin Luo, Quanliang Zou, Pan Chen, Liqin Pan, Man Long, Huijuan Feng, Wei Ouyang
Summary: This study aims to demonstrate the clinical efficacy and safety of sorafenib used in the treatment of radioactive iodine refractory differentiated thyroid cancer (RR-DTC) at Zhujiang Hospital of Southern Medical University. The results showed that sorafenib has promising efficacy in RR-DTC, especially in patients with lung metastasis and lung-only metastasis. The main adverse effect of sorafenib was hand-foot skin syndrome (HFS).
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Hang-Seok Chang, Yonjung Kim, So Young Lee, Hyeok Jun Yun, Ho-Jin Chang, Ki Cheong Park
Summary: Thyroid cancer can be curable but may recur after treatment. In this study, a novel SERCA inhibitor was identified in sorafenib-resistant thyroid cancer cells, which showed significant tumor shrinkage in a xenograft tumor model. These findings have important clinical implications for developing new strategies to target refractory cancer cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Yuna Kim, Hyeok Jun Yun, Kyung Hwa Choi, Chan Wung Kim, Jae Ha Lee, Raymond Weicker, Seok-Mo Kim, Ki Cheong Park
Summary: This study aimed to identify novel thyroid cancer target candidates by validating and identifying one of the many anti-cancer drug-resistant targets. Through virtual screening, the researchers discovered novel SERCA inhibitors that showed significant inhibition on sorafenib-resistant thyroid cancer cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Takuya Higashiyama, Kiminori Sugino, Hisato Hara, Ken-Ichi Ito, Noriaki Nakashima, Naoyoshi Onoda, Masayuki Tori, Hiroshi Katoh, Naomi Kiyota, Ichiro Ota, Nobuyasu Suganuma, Yatsuka Hibi, Toshimitsu Nemoto, Shunji Takahashi, Katsunari Yane, Tetsuya Ioji, Shinsuke Kojima, Hideaki Kaneda, Iwao Sugitani, Makoto Tahara
Summary: The study assessed the efficacy and safety of lenvatinib in patients with unresectable anaplastic thyroid cancer (ATC), revealing a low overall survival rate and a limited number of responders. However, responses were durable, suggesting potential benefits for selected patients.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Endocrinology & Metabolism
Yan-Song Lin, Xin Zhang, Chen Wang, Yan-Qing Liu, Wen-Min Guan, Jun Liang
Summary: The long-term evaluation of apatinib in patients with radioiodine refractory differentiated thyroid cancer showed sustainable efficacy and tolerable safety profile, especially for patients with BRAF(V600E) mutation.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Hematology
Blake S. Moses, Samantha McCullough, Jennifer M. Fox, Bryan T. Mott, Soren M. Bentzen, MinJung Kim, Jeffrey W. Tyner, Rena G. Lapidus, Ashkan Emadi, Michelle A. Rudek, Tami J. Kingsbury, Curt Civin
Summary: Artemisinins have shown synergy with BCL2 inhibitors in inhibiting leukemia cell growth and inducing apoptosis. The SAV regimen targets MCL1 and BCL2 through tolerable mechanisms, with MCL1 and DDIT3/CHOP levels potentially serving as biomarkers for the action of artemisinins and SAV.
Article
Medicine, Research & Experimental
Niels A. D. Guchelaar, Ruben A. G. van Eerden, Stefanie L. Groenland, Leni van Doorn, Ingrid M. E. Desar, Ferry A. L. M. Eskens, Neeltje Steeghs, Nielka P. van Erp, Alwin D. R. Huitema, Ron H. J. Mathijssen, Stijn L. W. Koolen
Summary: Therapeutic drug monitoring (TDM) for sorafenib is not of added value in daily clinical practice due to the limitations posed by toxicity that restrict dose escalations.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Oncology
Baukelien van Triest, Marnix Rasing, Jacobus van der Velden, Joanne de Hullu, Petronella O. Witteveen, Jannet C. Beukema, Elsbieta Van der Steen-Banasik, Henrike Westerveld, An Snyers, Max Peters, Carien L. Creutzberg, Remi A. Nout, Ludy Lutgens, Ina Jurgenliemk-Schulz
Summary: This study evaluated the feasibility of chemoradiation as an alternative to extensive surgery in patients with locally advanced vulvar cancer and reported on locoregional control, toxicity, and survival. The results showed that the treatment regimen was feasible and resulted in effective locoregional control with acceptable survival rates and manageable toxicity.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Endocrinology & Metabolism
Daniel J. van de Berg, Anke M. J. Kuijpers, Anton F. Engelsman, Caroline A. Drukker, Hanneke M. van Santen, Sheila C. E. J. Terwisscha van Scheltinga, A. S. Paul van Trotsenburg, Christiaan F. Mooij, Menno R. Vriens, Els J. M. Nieveen van Dijkum, Joep P. M. Derikx
Summary: This study describes the long-term oncological outcomes of pediatric papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC), and finds that recurrence rate is high in pediatric PTC but low in FTC. Pediatric PTC and FTC are two distinct diseases, but both have a good survival rate.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Mijin Kim, Meihua Jin, Min Ji Jeon, Eui Young Kim, Dong Yeob Shin, Dong Jun Lim, Bo Hyun Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Hee Kyung Kim, Won Gu Kim
Summary: This study aimed to evaluate the clinical efficacy and safety of sorafenib and lenvatinib as first-line treatment for RAI-refractory DTC. The results showed that lenvatinib had a longer PFS and more common adverse events compared to sorafenib.
Article
Biochemistry & Molecular Biology
J. N. C. Jayasinghe, Ilson Whang, Mahanama De Zoysa
Summary: In this study, Octominin was modified into Octominin II, which showed inhibitory effects on drug-resistant Candida albicans by employing different modes of action and reducing its pathogenicity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Endocrinology & Metabolism
Youhyun Song, Hye Sun Lee, Goeun Park, Sang-Wook Kang, Ji Won Lee
Summary: This study aimed to investigate the risk of dyslipidemia in patients with thyroid cancer (TC) compared to the general population without TC. The results showed no significant difference in dyslipidemia risk between TC patients and the general population, both in prospective and retrospective analyses.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Yoshimichi Haruna, Takayuki Yakushijin, Seiichi Kawamoto
Summary: The study confirmed that dosing vitamin K alongside sorafenib can significantly enhance its anticancer effects against hepatocellular carcinoma, leading to improved objective response rate and progression-free survival time. Patients who received vitamin K in addition to sorafenib also showed significantly extended overall survival time, especially those who achieved complete or partial response.
Article
Oncology
Mohammad Taher Parad, Mohammad Fararouei, Ali Reza Mirahmadizadeh, Sima Afrashteh
Summary: The study identified risk factors for thyroid cancer in a high-incidence region in Iran, including benign thyroid diseases, family history, radiation exposure, and family history of other cancers. Protective factors were found to be high blood pressure, higher education, unsaturated fat consumption, and being married. Community-based interventions such as reducing radiation exposure and screening family members with underlying thyroid diseases may help prevent or detect thyroid cancer early. Further studies on the health effects of local herbs are recommended.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Medicine, General & Internal
Chen-Yuan Lin, Jeffrey S. Chang, Shih-Ming Huang, Chung-Jye Hung, Chien-Ling Hung, Chwen-Tzuei Chang, Horng-Ren Yang, Te-Chun Hsieh, Yu-Hui Huang, Hui-Jen Tsai
Summary: In this study, we investigated the real-world experience of sorafenib in treating advanced DTC patients in Taiwan. Most patients started with a dose of 200 mg twice daily and had a mean daily maintenance dose of 433 mg. The most common toxicity of sorafenib was hand foot skin reaction (69%), followed by diarrhea (42%), and skin rash (33%).
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2021)
Review
Oncology
Akshat Malik, John C. Hardman, Yadsan Devabalan, Christopher Nutting, Shreerang Bhide, Kevin Harrington, Clare Schilling, Vinidh Paleri
Summary: A systematic review and meta-analysis was conducted to evaluate occult contralateral nodal metastases (OCM) in patients undergoing bilateral neck dissection for surgically treated oropharyngeal squamous cell carcinoma (OPSCC). The study found that OCM were seen in 9.8% of patients, with a higher rate in cN positive necks compared to cN0 necks. This highlights the importance of considering contralateral neck involvement in the surgical treatment of OPSCC.
Article
Oncology
Kevin J. Harrington, Barbara Burtness, Richard Greil, Denis Soulieres, Makoto Tahara, Gilberto de Castro Jr, Amanda Psyrri, Irene Brana, Neus Baste, Prakash Neupane, Ase Bratland, Thorsten Fuereder, Brett G. M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gumuscu, Ramona F. Swaby, Danny Rischin
Summary: The study presents a post hoc analysis of the long-term efficacy and progression-free survival in recurrent/metastatic head and neck squamous cell carcinoma patients treated with pembrolizumab and pembrolizumab-chemotherapy as next-line therapy. The results demonstrate favorable clinical efficacy and progression-free survival with pembrolizumab and pembrolizumab-chemotherapy in patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) >= 20, CPS >= 1, and total populations. Subsequent treatments after pembrolizumab-based therapy also showed good efficacy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
A. Psyrri, J. Fayette, K. Harrington, M. Gillison, M. -J. Ahn, S. Takahashi, J. Weiss, J. -P. Machiels, S. Baxi, A. Vasilyev, A. Karpenko, M. Dvorkin, C. -Y. Hsieh, S. C. Thungappa, P. P. Segura, I. Vynnychenko, R. Haddad, S. Kasper, P. -S. Mauz, V. Baker, P. He, B. Evans, S. Wildsmith, R. F. Olsson, A. Yovine, J. F. Kurland, N. Morsli, T. Y. Seiwert
Summary: The study compared the efficacy of durvalumab with or without tremelimumab versus the EXTREME regimen in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The results showed that in patients with high PD-L1 expression, durvalumab had comparable overall survival with the EXTREME regimen. However, durvalumab alone and in combination with tremelimumab showed durable responses and reduced treatment-related adverse events compared to the EXTREME regimen.
ANNALS OF ONCOLOGY
(2023)
Review
Oncology
Robert L. Ferris, Kevin Harrington, Jonathan D. Schoenfeld, Makoto Tahara, Christina Esdar, Satu Salmio, Andreas Schroeder, Jean Bourhis
Summary: Standard of care for patients with locally advanced squamous cell carcinoma of the head and neck is surgery followed by chemoradiotherapy or definitive chemoradiotherapy. However, many patients experience disease recurrence or metastasis within 2 years, indicating a need for novel treatment options. Overexpression of inhibitor of apoptosis proteins (IAPs) has been identified as a key factor in treatment resistance and poor outcomes. Xevinapant, a potent IAP inhibitor, has shown promising results in combination with chemoradiotherapy in a phase 2 trial. This article explores the current treatment landscape and highlights the potential of targeting IAPs for improved outcomes.
CANCER TREATMENT REVIEWS
(2023)
Article
Oncology
Robert I. Haddad, Kevin Harrington, Makoto Tahara, Robert L. Ferris, Maura Gillison, Jerome Fayette, Amaury Daste, Piotr Koralewski, Bogdan Zurawski, Miren Taberna, Nabil F. Saba, Milena Mak, Andrzej Kawecki, Gustavo Girotto, Miguel Angel Alvarez Avitia, Caroline Even, Joaquin Gabriel Reinoso Toledo, Alexander Guminski, Urs Muller-Richter, Naomi Kiyota, Mustimbo Roberts, Tariq Aziz Khan, Karen Miller-Moslin, Li Wei, Athanassios Argiris
Summary: In patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), first-line nivolumab plus ipilimumab did not show a significant difference in overall survival compared to the standard treatment. However, there may be some advantages in certain populations, and it has a better safety profile.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Charles M. Rudin, Hardev S. Pandha, Matthew Zibelman, Wallace L. Akerley, Kevin J. Harrington, Daphne Day, Andrew G. Hill, Steven J. O'Day, Timothy D. Clay, Gavin M. Wright, Ross R. Jennens, David E. Gerber, Jonathan E. Rosenberg, Christy Ralph, David C. Campbell, Brendan D. Curti, Jaime R. Merchan, Yixin Ren, Emmett Schmidt, Lisa Guttman, Sumati Gupta
Summary: This study evaluated the efficacy and safety of V937 combined with pembrolizumab in patients with advanced solid tumors. The results showed that the combination therapy had a manageable safety profile, but did not achieve greater efficacy than pembrolizumab monotherapy in non-small cell lung cancer and urothelial cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Robert I. Haddad, Kevin Harrington, Makoto Tahara, Petr Szturz, Christophe Le Tourneau, Satu Salmio, Marcis Bajars, Nancy Y. Lee
Summary: For the last 20 years, cisplatin-based chemoradiotherapy has been the standard treatment for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) patients at high risk of recurrence. However, many patients are ineligible for this treatment due to various reasons. The criteria for cisplatin ineligibility, including age and renal impairment, are still debated. The proportion of cisplatin ineligible patients with resected LA SCCHN remains unclear. This review discusses cisplatin ineligibility considerations, limited clinical evidence, and ongoing clinical trials for alternative treatment options.
CANCER TREATMENT REVIEWS
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Cara Owens, Alex Fitzhugh, Kevin Harrington, Vinidh Paleri, Bhupinder Sharma, Joshua Shur, Derfel ap Dafydd
Summary: This retrospective study assessed the clinical outcomes of patients with a primary malignancy who had incidentally detected thyroid cancer on their F-18-FDG PET-CT imaging. After a search of imaging records, patient demographics, oncological diagnosis, and stage were recorded. The results showed that the clinical outcomes of patients with an established primary malignancy are determined by their primary cancer and not by incidentally detected thyroid cancer, suggesting a potential 'watch-and-wait' approach for incidental thyroid nodules.
NUCLEAR MEDICINE COMMUNICATIONS
(2023)
Article
Oncology
Fabiana Gregucci, Sheila Spada, Mary Helen Barcellos-Hoff, Nina Bhardwaj, Charleen Chan Wah Hak, Alba Fiorentino, Chandan Guha, Monica L. Guzman, Kevin Harrington, Fernanda G. Herrera, Jamie Honeychurch, Theodore Hong, Lorea Iturri, Elisabeth Jaffee, Sana D. Karam, Simon R. V. Knott, Constantinos Koumenis, David Lyden, Ariel E. Marciscano, Alan Melcher, Michele Mondini, Anna Mondino, Zachary S. Morris, Sean Pitroda, Sergio A. Quezada, Laura Santambrogio, Stephen Shiao, John Stagg, Irma Telarovic, Robert Timmerman, Marie-Catherine Vozenin, Ralph Weichselbaum, James Welsh, Anna Wilkins, Chris Xu, Roberta Zappasodi, Weiping Zou, Alexandre Bobard, Sandra Demaria, Lorenzo Galluzzi, Eric Deutsch, Silvia C. Formenti
Summary: Focal radiation therapy has potential as a partner for immunotherapy, but there is a need for a better understanding of their interaction. The ImmunoRad conference provides a platform for experts to share knowledge and promote progress in the field. This article summarizes the key concepts and findings presented at the Sixth Annual ImmunoRad conference.
Article
Oncology
Kevin J. Harrington, Robert L. Ferris, Maura Gillison, Makoto Tahara, Athanasios Argiris, Jerome Fayette, Michael Schenker, Ase Bratland, John W. T. Walker, Peter Grell, Caroline Even, Christine H. Chung, Rebecca Redman, Alexandre Coutte, Sebastien Salas, Cliona Grant, Sergio de Azevedo, Denis Soulieres, Aaron R. Hansen, Li Wei, Tariq Aziz Khan, Karen Miller-Moslin, Mustimbo Roberts, Robert Haddad
Summary: The clinical benefit of first-line nivolumab plus ipilimumab was evaluated in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). The study found that nivolumab plus ipilimumab did not improve clinical outcomes compared to nivolumab alone in these patients. Further research is needed to identify subpopulations of R/M SCCHN patients who would benefit from nivolumab plus ipilimumab therapy.
Article
Oncology
Alexandra J. Rose, Mercedes M. Fleming, Jeffrey C. Francis, Jian Ning, Anton Patrikeev, Ritika Chauhan, Kevin J. Harrington, Amanda Swain
Summary: This study established patient-derived xenograft (PDX) lines and tumor organoid models for salivary gland adenoid cystic carcinoma (ACC), and demonstrated the inhibitory effect of dBET6 on ACC cells. Molecular studies revealed a decrease in BRD4 and MYB protein levels and target gene expression with dBET6 treatment. In vivo experiments showed that dBET6 altered the relative composition of ACC cell types and inhibited their progenitor function.
JOURNAL OF PATHOLOGY
(2023)
Article
Oncology
Karan Patel, Massimiliano Manzo, Brindley Hapuarachi, Samuel Rack, Philip Jermann, Laura Feeney, Emily Heathcote, Guy Betts, Jon C. Aster, Maximilien Murone, Maria Bobadilla, Rajwinder Lehal, Florian D. Vogl, Kevin Harrington, Robert Metcalf
Review
Oncology
Rita Simoes, Yolanda Augustin, Sarah Gulliford, Hakim-Moulay Dehbi, Peter Hoskin, Elizabeth Miles, Kevin Harrington, Aisha B. Miah
Summary: This systematic review summarizes the incidence of acute and late toxicities in soft tissue sarcoma of the extremities (STSE) patients undergoing radiotherapy. It also discusses the limitations in guidance on normal tissue and dose-volume parameters for optimizing radiotherapy plans in STSE.
RADIOTHERAPY AND ONCOLOGY
(2023)
Review
Oncology
Patricia P. Centeno, Valeria Pavet, Richard Marais
Summary: In the past decade, significant progress has been made in new cancer treatments for melanoma, particularly in on-treatment survival. However, overall survival rates have improved relatively modestly. Melanoma exhibits heterogeneity and transcriptional plasticity, enabling it to adapt and escape even advanced treatments. Although our understanding of melanoma biology and genetics has advanced, debates continue regarding the cell of origin for melanoma. Animal models and single-cell sequencing approaches offer new avenues of research in addressing this question.
NATURE REVIEWS CANCER
(2023)
Article
Oncology
K. J. Harrington, E. E. W. Cohen, D. Soulieres, J. Dinis, L. Licitra, M. -j. Ahn, A. Soria, J. -p. Machiels, N. Mach, R. Mehra, B. Burtness, R. F. Swaby, J. Lin, J. Ge, N. Lerman, C. Le Tourneau
Summary: Through a study on patients with HNSCC, it was found that pembrolizumab provided longer overall survival and durable responses in all subgroups of recurrence patterns, regardless of previous treatment.